Don't understand why anyone would sell this for under 2 million MC - the EV of all of AGX's ventures is effectively valued by the market at a big fat ZERO
Some facts about AGX (from its last preso)
? ThromboView : For Blood Clot Diagnosis. Phase III ready. $38.5m capital has been expended on development and Phase 1 and 2 human trials. Currently AGX is looking for a partner and it has been looking since october last year
- DiagnostIQ: point of care rapid diagnostic platform can be partnered for multiple tests. AGX is partnered with Arrayjet Limited (Scotland) to develop microarray platform
- Directors hold 22% of shares
- Very low cash burn rate for a biotech in phase 3 (anyone have a figure on the costs for phase 3?)
-Top 20 shareholders hold 64.8% of shares
Extremely frustrated that I entered at 1.7 and then got sh*t out minutes later. Ideally would have gotten stopped out but fundamentals seem nice so I guess this is one of the failed-STT-becoming medium term holds LOL.
- Forums
- ASX - By Stock
- cash flow
Don't understand why anyone would sell this for under 2 million...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $1.5K | 750K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
33 | 30509998 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 6098307 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
33 | 30509998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.002 | 6098307 | 10 |
0.003 | 19186238 | 7 |
0.004 | 3800214 | 2 |
0.005 | 2000000 | 1 |
0.006 | 1000000 | 1 |
Last trade - 13.23pm 22/05/2024 (20 minute delay) ? |
Featured News
CT1 (ASX) Chart |
The Watchlist
RDN
RAIDEN RESOURCES LIMITED
Dusko Ljubojevic, MD
Dusko Ljubojevic
MD
SPONSORED BY The Market Online